Rhode Island Chronicle

Heart Failure Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | GlaxoSmithKline, Eli Lilly and Company, Salubris Biotherapeutics

 Breaking News
  • No posts were found

Heart Failure Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | GlaxoSmithKline, Eli Lilly and Company, Salubris Biotherapeutics

May 25
19:28 2023
Heart Failure Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | GlaxoSmithKline, Eli Lilly and Company, Salubris Biotherapeutics
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Heart Failure pipeline constitutes 75+ key companies continuously working towards developing 90+ Heart Failure treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Heart Failure Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Heart Failure Market.

 

The Heart Failure Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Heart Failure Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Heart Failure treatment therapies with a considerable amount of success over the years. 
  • Heart Failure companies working in the treatment market are GlaxoSmithKline, Eli Lilly and Company, Salubris Biotherapeutics, Heartseed Inc., Sardocor Corp., Help Therapeutics, Bristol Myers Squibb, Rivus Pharmaceuticals, Palatin Technologies, AstraZeneca, Mesoblast, Bayer, Eli Lilly and Company, and others, are developing therapies for the Heart Failure treatment 
  • Emerging Heart Failure therapies such as – GSK3884464, LY 3461767, JK07, HS-001, SRD-001, hiPSC-CM therapy, Mavacamten, HU 6, PL 3994, AZD9977, Rexlemestrocel-L, Finerenone, Tirzepatide, and others are expected to have a significant impact on the Heart Failure market in the coming years.   
  • In February 2023, The Journal of the American College of Cardiology (JACC), the top peer-reviewed journal for cardiovascular medicine, has published the DREAM-HF Phase 3 study data, according to Mesoblast Limited
  • On 31 October 2022, Impella RP Flex, an easier-to-wear pump from Abiomed, was given FDA approval for treating right-sided heart failure
  • In October 2022, Cardiologists and vascular surgeons at Allegheny General Hospital reported that they had successfully implanted a brand-new Barostim device for the first time in Pittsburgh, which is designed to treat patients with progressive heart failure

 

Heart Failure Overview

Heart failure (HF) is a syndrome brought on by anatomical and functional myocardial abnormalities that limit ventricular filling or cause blood to be ejected. Reduced left ventricular myocardial function is the main cause of Heart Failure.

 

Get a Free Sample PDF Report to know more about Heart Failure Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight

 

Emerging Heart Failure Drugs Under Different Phases of Clinical Development Include:

  • GSK3884464: GlaxoSmithKline
  • LY 3461767: Eli Lilly and Company
  • JK07: Salubris Biotherapeutics
  • HS-001: Heartseed Inc.
  • SRD-001: Sardocor Corp.
  • hiPSC-CM therapy: Help Therapeutics
  • Mavacamten: Bristol Myers Squibb
  • Firibastat: Quantum Genomics
  • HU 6: Rivus Pharmaceuticals
  • PL 3994: Palatin Technologies
  • AZD9977: AstraZeneca
  • Rexlemestrocel-L: Mesoblast
  • Finerenone: Bayer
  • CardiAMP Cell Therapy: BioCardia
  • Tirzepatide: Eli Lilly and Company

 

Route of Administration

Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Heart Failure Pipeline Therapeutics Assessment

  • Heart Failure Assessment by Product Type
  • Heart Failure By Stage and Product Type
  • Heart Failure Assessment by Route of Administration
  • Heart Failure By Stage and Route of Administration
  • Heart Failure Assessment by Molecule Type
  • Heart Failure by Stage and Molecule Type

 

DelveInsight’s Heart Failure Report covers around 90+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Heart Failure product details are provided in the report. Download the Heart Failure pipeline report to learn more about the emerging Heart Failure therapies

 

Some of the key companies in the Heart Failure Therapeutics Market include:

Key companies developing therapies for Heart Failure are – General Electric Company, Boston Scientific Corporation, Medtronic, St. Jude Medical, Inc., Biotronik SE & Co. KG, LivaNova PLC, Shree Pacetronix Ltd., OSCOR Inc., MEDICO S.p.A., Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Edwards Lifesciences, Zoll Medical Corporation, Vitatron, Osypka Medical, Inc., Cook Medical, Abbott, CorWave SA, Berlin Heart GmbH, Jarvik Heart, Inc., and several others.

 

Heart Failure Pipeline Analysis:

The Heart Failure pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Heart Failure with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Heart Failure Treatment.
  • Heart Failure key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Heart Failure market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Heart Failure drugs and therapies

 

Heart Failure Pipeline Market Drivers

  • Biomarkers helps in understanding the complexity of heart failure, recent advancements in research and development, rising geriatric population are some of the important factors that are fueling the Heart Failure Market.

 

Heart Failure Pipeline Market Barriers

  • However, biomarkers helps in understanding the complexity of heart failure, recent advancements in research and development, rising geriatric population and other factors are creating obstacles in the Heart Failure Market growth.

 

Scope of Heart Failure Pipeline Drug Insight    

  • Coverage: Global
  • Key Heart Failure Companies: GlaxoSmithKline, Eli Lilly and Company, Salubris Biotherapeutics, Heartseed Inc., Sardocor Corp., Help Therapeutics, Bristol Myers Squibb, Rivus Pharmaceuticals, Palatin Technologies, AstraZeneca, Mesoblast, Bayer, Eli Lilly and Company, and others
  • Key Heart Failure Therapies: GSK3884464, LY 3461767, JK07, HS-001, SRD-001, hiPSC-CM therapy, Mavacamten, HU 6, PL 3994, AZD9977, Rexlemestrocel-L, Finerenone, Tirzepatide, and others
  • Heart Failure Therapeutic Assessment: Heart Failure current marketed and Heart Failure emerging therapies
  • Heart Failure Market Dynamics: Heart Failure market drivers and Heart Failure market barriers 

 

Request for Sample PDF Report for Heart Failure Pipeline Assessment and clinical trials

 

Table of Contents

1

Heart Failure Report Introduction

2

Heart Failure Executive Summary

3

Heart Failure Overview

4

Heart Failure- Analytical Perspective In-depth Commercial Assessment

5

Heart Failure Pipeline Therapeutics

6

Heart Failure Late Stage Products (Phase II/III)

7

Heart Failure Mid Stage Products (Phase II)

8

Heart Failure Early Stage Products (Phase I)

9

Heart Failure Preclinical Stage Products

10

Heart Failure Therapeutics Assessment

11

Heart Failure Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Heart Failure Key Companies

14

Heart Failure Key Products

15

Heart Failure Unmet Needs

16 

Heart Failure Market Drivers and Barriers

17

Heart Failure Future Perspectives and Conclusion

18

Heart Failure Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Categories